Marker: Pre-Clinical Data for MT-601 MultiTAA-Specific T Cell Product in Lymphoma

 MT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro

 Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced pre-clinical data from the Company’s multiple tumor-associated antigens (multiTAA)-specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells.

https://finance.yahoo.com/news/marker-therapeutics-reports-pre-clinical-103000977.html